Idiopathic deep vein thrombosis and the duration of low-intensity warfarin
Thank you for your comments about the use of low intensity warfarin.
The two studies ELATE and PREVENT are of great clinical importance
and it is likely that many patients in the future will be treated with a
low-intensity warfarin regimen.
The PREVENT trial was not published until April 2003 and it was too
late to have included in our paper. As we were confined to 2000 words I
did not discuss the possibility of using low intensity warfarin.
I am grateful that you have highlighted these two recent studies.
I have been reimbursed by Pharmacia, the manufacturers of Fragmin, for attending a conference
Competing interests: No competing interests